Monte Rosa Therapeutics to Present Phase 1 Study Results

Monte Rosa Therapeutics will present results from its MRT-8102 GFORCE-1 Phase 1 study in subjects with elevated cardiovascular disease risk. A conference call and webcast will be held on October 1, 2026.